# Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

Article · Filip Krag Knop, Vanita R. Aroda, Ruben Duque do Vale, Thomas Holst‐Hansen, Peter Nørkjær Laursen, Julio Rosenstock, Domenica Rubino, William Timothy Garvey

- Archive id: doi:10.1016/s0140-6736(23)01185-6
- Published: 2023-06-25
- Venue: The Lancet
- DOI: https://doi.org/10.1016/s0140-6736(23)01185-6
- PMID: 37385278
- Citations: 430
- Source URL: https://doi.org/10.1016/s0140-6736(23)01185-6
- Provenance: openalex

_Abstract not reproduced: its license does not permit redistribution. See the source URL._

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

Cited in dossiers:
- [GLP-1 & Incretin Therapies: State of the Field (October 2026)](https://space-kitty.com/dossiers/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.